Xenon Pharmaceuticals Inc. announced equity inducement grants to six new non-officer employees totaling 24,200 share options, approved by the Compensation Committee with an exercise price of $30.54 per common share. The share options vest over four years and have a 10-year term, subject to continued service with the company. Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing therapeutics for epilepsy and depression, with Azetukalner as a leading potassium channel modulator in late-stage clinical development. For more information, visit www.xenon-pharma.com. Contact [email protected] for investor relations and [email protected] for media inquiries.

Read more at GlobeNewswire: Xenon Pharmaceuticals Reports Inducement Grants Under